arrow
J

Jacqulyne Robichaux

md anderson cancer center
H指数:20
被引数:3,005

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

poziotinib 用于 EGFR 外显子 20 插入型 NSCLC:ZENITH II 期试验的临床疗效及 EGFR 外显子 20 插入位点对敏感性的差异化影响

2025-09-240
OAAI
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)
2024-08-200
OA
FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
2024-04-054
PRE
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
2020-09-02119
OAAI
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
2019-01-0145
PREAI
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

奥希替尼的EGFR依赖性和非依赖性耐药机制以及EGFR突变型NSCLC进展后继续治疗的前景

2018-12-13306
OAAI
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
2018-04-23378
OAAI